Alzamend Neuro annual r&d spending
2020
2021
2022
2023
2024
2025
2026
Alzamend Neuro R&D Spending Growth & History (ALZN)
Alzamend Neuro's r&d spending was $3.6M for fiscal 2026.
View full Alzamend Neuro company overviewAlzamend Neuro annual r&d spending history
| Fiscal year | Period ended | R&D spending | Change | Growth |
|---|---|---|---|---|
| 2026 | 2026-04-30 | $3.6M | $2.2M | +156.53% |
| 2025 | 2025-04-30 | $1.4M | −$5.0M | −78.08% |
| 2024 | 2024-04-30 | $6.5M | −$990,750 | −13.31% |
| 2023 | 2023-04-30 | $7.4M | $2.2M | +43.15% |
| 2022 | 2022-04-30 | $5.2M | $3.9M | +296.83% |
| 2021 | 2021-04-30 | $1.3M | $241,298 | +22.56% |
| 2020 | 2020-04-30 | $1.1M | — | — |
Alzamend Neuro quarterly r&d spending
Q1.21
Q2.21
Q3.21
Q4.21
Q1.22
Q2.22
Q3.22
Q4.22
Q1.23
Q2.23
Q3.23
Q4.23
Q1.24
Q2.24
Q3.24
Q4.24
Q1.25
Q2.25
Q3.25
Q4.25
Q1.26
Q2.26
Q3.26
Q4.26
| Fiscal quarter | Period ended | R&D spending | Change | YoY change |
|---|---|---|---|---|
| Q4 2026 | 2026-04-30 | $434,006 | −$16,152 | −3.59% |
| Q3 2026 | 2026-01-31 | $1.3M | $831,518 | +185.98% |
| Q2 2026 | 2025-10-31 | $176,283 | −$134,805 | −43.33% |
| Q1 2026 | 2025-07-31 | $1.7M | $1.5M | +742.75% |
| Q4 2025 | 2025-04-30 | $450,158 | $266,728 | +145.41% |
| Q3 2025 | 2025-01-31 | $447,111 | −$1.5M | −76.58% |
| Q2 2025 | 2024-10-31 | $311,088 | −$1.7M | −84.42% |
| Q1 2025 | 2024-07-31 | $206,571 | −$2.2M | −91.27% |
| Q4 2024 | 2024-04-30 | $183,430 | −$1.5M | −88.87% |
| Q3 2024 | 2024-01-31 | $1.9M | −$980,090 | −33.93% |
| Q2 2024 | 2023-10-31 | $2.0M | $463,798 | +30.25% |
| Q1 2024 | 2023-07-31 | $2.4M | $990,184 | +71.96% |
| Q4 2023 | 2023-04-30 | $1.6M | −$13,131 | −0.79% |
| Q3 2023 | 2023-01-31 | $2.9M | $2.0M | +230.66% |
| Q2 2023 | 2022-10-31 | $1.5M | −$217,065 | −12.40% |
| Q1 2023 | 2022-07-31 | $1.4M | $459,545 | +50.15% |
| Q4 2022 | 2022-04-30 | $1.7M | $1.4M | +467.55% |
| Q3 2022 | 2022-01-31 | $873,653 | $639,391 | +272.94% |
| Q2 2022 | 2021-10-31 | $1.8M | $1.3M | +268.50% |
| Q1 2022 | 2021-07-31 | $916,408 | $607,562 | +196.72% |
| Q4 2021 | 2021-04-30 | $292,695 | — | — |
| Q3 2021 | 2021-01-31 | $234,262 | — | — |
| Q2 2021 | 2020-10-31 | $474,913 | — | — |
| Q1 2021 | 2020-07-31 | $308,846 | — | — |
Alzamend Neuro r&d spending trends
Over the last five fiscal years, Alzamend Neuro's r&d spending increased from $1.3M to $3.6M, a change of $2.3M. The latest reported quarter, Q4 2026, shows $434,006.
About the metric
What research and development spending means
Research and development (R&D) spending covers the costs of creating and improving products, services, software, technologies, and processes. Higher R&D spending may support future innovation, but the amount alone does not show whether those investments will generate returns.
Calculation and source
SEC-reported R&D expense
TickerStat standardizes research and development expense reported in company SEC filings, including the software-specific US-GAAP R&D concept when it is the filer’s primary R&D expense line. It is historical company-reported spending, not an estimate or forecast. Fiscal periods can differ from calendar years, so exact period-end dates are included.
Review Alzamend Neuro source filings ↗